Simon Borghs
Title
Cited by
Cited by
Year
An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam
SL Yates, T Fakhoury, W Liang, K Eckhardt, S Borghs, J D'Souza
Epilepsy & Behavior 52, 165-168, 2015
1022015
Defining minimally important change in QOLIE-31 scores: estimates from three placebo-controlled lacosamide trials in patients with partial-onset seizures
S Borghs, C de la Loge, JA Cramer
Epilepsy & Behavior 23 (3), 230-234, 2012
542012
Safety, tolerability, and seizure control during long‐term treatment with adjunctive brivaracetam for partial‐onset seizures
M Toledo, J Whitesides, J Schiemann, ME Johnson, K Eckhardt, ...
Epilepsia 57 (7), 1139-1151, 2016
462016
Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial
WW Zadeh, A Escartin, W Byrnes, F Tennigkeit, S Borghs, T Li, ...
Seizure 31, 72-79, 2015
352015
Randomized double-blind comparison of cognitive and EEG effects of lacosamide and carbamazepine
KJ Meador, DW Loring, A Boyd, J Echauz, S LaRoche, N Velez-Ruiz, ...
Epilepsy & Behavior 62, 267-275, 2016
282016
PatientsLikeMeŽ Online Epilepsy Community: Patient characteristics and predictors of poor health-related quality of life
C de la Loge, S Dimova, K Mueller, G Phillips, TL Durgin, P Wicks, ...
Epilepsy & Behavior 63, 20-28, 2016
232016
Comparing generic and condition-specific preference-based measures in epilepsy: EQ-5D-3L and NEWQOL-6D
B Mulhern, J Pink, D Rowen, S Borghs, T Butt, D Hughes, A Marson, ...
Value in Health 20 (4), 687-693, 2017
172017
Determining minimally important change thresholds for the Seizure Severity Questionnaire (SSQ)
JA Cramer, C de la Loge, Y Brabant, S Borghs
Epilepsy & Behavior 31, 286-290, 2014
162014
Long-term retention rates for antiepileptic drugs: a review of long-term extension studies and comparison with brivaracetam
M Toledo, R Beale, JS Evans, S Steeves, S Elmoufti, R Townsend, ...
Epilepsy research 138, 53-61, 2017
152017
Health care cost associated with the use of enzyme-inducing and non-enzyme–active antiepileptic drugs in the UK: a long-term retrospective matched cohort study
S Borghs, S Thieffry, M Noack-Rink, P Dedeken, L San Hong, L Byram, ...
BMC neurology 17 (1), 1-11, 2017
122017
Sensitivity testing of the seizure severity questionnaire (SSQ)
S Borghs, C de la Loge, Y Brabant, J Cramer
Epilepsy & Behavior 31, 281-285, 2014
102014
META-ANALYSIS OF NONPSYCHOTIC BEHAVIORAL TREATMENT EMERGENT ADVERSE EVENTS IN BRIVARACETAM AND LEVETIRACETAM DEVELOPMENT PROGRAMS: p402
J D'Souza, M Johnson, S Borghs
Epilepsia 53, 2012
102012
Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures
V Farkas, B Steinborn, JR Flamini, Y Zhang, N Yuen, S Borghs, A Bozorg, ...
Neurology 93 (12), e1212-e1226, 2019
92019
Lacosamide and sodium channel‐blocking antiepileptic drug cross‐titration against levetiracetam background therapy
M Baulac, W Byrnes, P Williams, S Borghs, E Webster, M De Backer, ...
Acta Neurologica Scandinavica 135 (4), 434-441, 2017
92017
Real life pharmaceutical treatment patterns for adult patients with focal epilepsy in Germany: a longitudinal and cross-sectional analysis of recently approved anti-epileptic drugs
A Groth, T Wilke, S Borghs, P Gille, L Joeres
GMS German Medical Science 15, 2017
92017
Health-related quality of life in double-blind phase III studies of brivaracetam as adjunctive therapy of focal seizures: a pooled, post-hoc analysis
C Brandt, S Borghs, S Elmoufti, K Mueller, R Townsend, C de la Loge
Epilepsy & Behavior 69, 80-85, 2017
62017
Trends in antiepileptic drug treatment and effectiveness in clinical practice in England from 2003 to 2016: a retrospective cohort study using electronic medical records
G Powell, J Logan, V Kiri, S Borghs
BMJ open 9 (12), e032551, 2019
52019
Improved Seizure Severity, Health-Related Quality of Life and Health Status Reported by Patients during Long-Term Treatment with Lacosamide: Analysis of Pooled Open-Label Data …
J Cramer, S Borghs, M De Backer, P Doty
Neurology 78 (Meeting Abstracts 1), PD3. 008, 2012
52012
Long‐term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11‐year, open‐label …
TJ O’Brien, S Borghs, Q He, AL Schulz, S Yates, V Biton
Epilepsia 61 (4), 636-646, 2020
42020
Relative performance of brivaracetam as adjunctive treatment of focal seizures in adults: a network meta-analysis
M Charokopou, R Harvey, K Srivastava, C Brandt, S Borghs
Current medical research and opinion 35 (8), 1345-1354, 2019
42019
The system can't perform the operation now. Try again later.
Articles 1–20